Agilent touts study of FTIR-based saliva COVID test

By staff writers

February 24, 2022 -- Agilent Technologies is highlighting a recent study that shows its Cary 630 Fourier transform infrared (FTIR) Spectrometer may be a simple, robust method for COVID-19 saliva screening.

FTIR spectroscopy provides a biochemical snapshot of samples and was recently used in proof-of-concept cohort studies for COVID-19 saliva screening. However, the biological basis of the proposed technology has not been established.

Authors of this latest study published in Biomedicines used Agilent's Cary 630 FTIR Spectrometer in controlled infection experiments on Vero E6 cells in vitro and K18-hACE2 mice in vivo. The researchers acquired infrared spectra of saliva samples following a quick and simple sample preparation requiring only ethanol and basic laboratory equipment.

Results demonstrated the utility of the Cary 630 FTIR Spectrometer in advanced infectious disease research, according to the company. Specifically, the instrument's ultracompact, portable, and reliable design make it ideal for seamless deployment in different settings and scenarios in infectious disease research, Agilent said.

Agilent acquires Virtual Control's lab AI technology
Agilent has acquired artificial intelligence (AI) technology developed by Virtual Control, a software development company for laboratory solutions. Agilent...
Agilent highlights automation platforms at SLAS 2022
Agilent Technologies highlighted the company's integrated automation platforms, including a live cell analysis system at the Society for Laboratory Automation...
Agilent receives FDA approval for breast cancer assay
Agilent Technologies has received approval from the U.S. Food and Drug Administration (FDA) for its Ki-67 IHC MIB-1 pharmDx assay. The assay can help...
Agilent enters digital pathology with Visiopharm deal
Agilent Technologies and Visiopharm have signed a worldwide distribution agreement that allows Agilent to co-market Visiopharm's portfolio of digital...
Agilent secures expanded CE Mark for cancer assay
Agilent Technologies has received an expanded CE Mark that will allow its PD-L1 IHC 22C3 pharmDx assay -- a companion diagnostic for the Keytruda chemotherapy...

Copyright © 2022

Last Updated ls 2/24/2022 3:16:46 PM

Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current